Biohaven (BHVN) Common Equity (2021 - 2026)
Biohaven (BHVN) posted Common Equity of $129.5 million for Q1 2026, up 148.69% sequentially from $52.1 million in Q4 2025, and up 177297.26% YoY from N/an in Q1 2025.
Biohaven (BHVN) Common Equity (2021 - 2026) Analysis & Trends
Biohaven has reported Common Equity for 6 years, with the latest figure at $129.5 million in Q1 2026.
- Quarterly Common Equity rose 177297.26% year-over-year to $129.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.5 million (up 177297.26% YoY) and the FY2025 annual result came in at $52.1 million, up 103.87% from the prior year.
- Common Equity advanced to $129.5 million in Q1 2026 per BHVN's latest filing, from $52.1 million in the prior quarter.
- Over five years, Common Equity peaked at $911.0 million in Q1 2024 and troughed at -$1.3 billion in Q4 2024.
- A 5-year average of -$7.9 million and a median of $25.0 million in 2022 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 548673.49% in 2024, down 733562.66% in 2024.
- Over 5 years, Common Equity stood at $538.8 million in 2022, then fell by 20.56% to $428.0 million in 2023, then plunged by 414.44% to -$1.3 billion in 2024, then jumped by 103.87% to $52.1 million in 2025, then surged by 148.69% to $129.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $129.5 million, $52.1 million, and -$17.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - | 12.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.22 Mn |
| Mar 31, 2026 | 129.50 Mn |
| Dec 31, 2025 | 52.07 Mn |
| Sep 30, 2025 | -17.16 Mn |
| Jun 30, 2025 | 157.02 Mn |
| Mar 31, 2025 | 73,000.00 |
| Dec 31, 2024 | -1.35 Bn |
| Sep 30, 2024 | -1.16 Bn |
| Jun 30, 2024 | -75,000.00 |
| Mar 31, 2024 | 910.96 Mn |
| Dec 31, 2023 | 427.98 Mn |
| Sep 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 282,000.00 |
| Mar 31, 2023 | 166,000.00 |
| Dec 31, 2022 | 538.77 Mn |
| Sep 30, 2022 | 100.22 Mn |
| Jun 30, 2022 | 25.00 Mn |
| Mar 31, 2022 | 46.10 Mn |
| Dec 31, 2021 | 34.69 Mn |
| Sep 30, 2021 | 321.51 Mn |